News >

Larotrectinib Likely to Get EU Nod for NTRK+ Tumors

Jason M. Broderick @jasoncology
Published: Friday, Jul 26, 2019

Scott Z. Fields, MD

Scott Z. Fields, MD
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of larotrectinib (Vitrakvi) for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.1

The overall response rate (ORR) with the TRK inhibitor larotrectinib was 72% (95% CI, 62-81) in the primary pooled analysis population, comprising a 16% complete response (CR) rate and 55% partial response (PR) rate. When including the primary CNS patients in the analysis, the ORR was 67% (95% CI, 57-76), comprising a 15% CR and 51% PR.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x